Royal Bank of Canada Lowers Hookipa Pharma (NASDAQ:HOOK) Price Target to $48.00

Hookipa Pharma (NASDAQ:HOOK) had its price target lowered by investment analysts at Royal Bank of Canada from $50.00 to $48.00 in a research note issued to investors on Friday, MarketBeat Ratings reports. The brokerage currently has an “outperform” rating on the stock.

Separately, JMP Securities upped their price objective on Hookipa Pharma from $23.00 to $24.00 and gave the company a “market outperform” rating in a research note on Friday, August 9th.

Hookipa Pharma Trading Down 4.5 %

NASDAQ HOOK opened at $3.00 on Friday. The business has a fifty day simple moving average of $4.09 and a 200 day simple moving average of $5.74. Hookipa Pharma has a 12 month low of $2.85 and a 12 month high of $11.30. The firm has a market capitalization of $36.18 million, a P/E ratio of -0.69 and a beta of 0.84.

Institutional Investors Weigh In On Hookipa Pharma

A number of hedge funds have recently modified their holdings of the stock. Virtu Financial LLC purchased a new stake in Hookipa Pharma in the first quarter worth $31,000. Ikarian Capital LLC bought a new position in shares of Hookipa Pharma during the 3rd quarter worth $228,000. Renaissance Technologies LLC increased its holdings in Hookipa Pharma by 38.4% in the 2nd quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock worth $179,000 after acquiring an additional 83,800 shares during the last quarter. Finally, Acadian Asset Management LLC raised its stake in Hookipa Pharma by 85.8% in the 1st quarter. Acadian Asset Management LLC now owns 882,262 shares of the company’s stock valued at $627,000 after acquiring an additional 407,532 shares during the period. Institutional investors own 63.88% of the company’s stock.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.